Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 23 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
13 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
GLOBIPHARM from Kontich, company number BE0843002254, closed financial year 2025 with a result of € 16,399 after tax. For that financial year GLOBIPHARM recorded a gross margin of € 65,582 and equity of € 90,837. Compared with financial year 2024, the result moved from € 19,641 to € 16,399. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on April 9, 2026.
€ 90,837
▲ 22% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 16,399
▼ 17% vs 2024
Profit after tax over the fiscal year.
€ 2,822
▲ 57% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 84,637.
Debts at end 2025
€ 423,592
▼ 12% vs 2024
€ 56,349 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.
€ 8,170
▲ 38% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 11,142
▼ 12% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 77,472 | € 83,252 | € 69,752 | € 65,582 | ▼ 6% |
| Profit after taxes | € 35,881 | € 29,955 | € 19,641 | € 16,399 | ▼ 17% |
| Equity | € 44,841 | € 54,796 | € 74,437 | € 90,837 | ▲ 22% |
| Total debts | € 603,700 | € 569,291 | € 497,615 | € 449,903 | ▼ 10% |
| Cash | € 30,974 | € 26,724 | € 1,797 | € 2,822 | ▲ 57% |
| Land & buildings | € 601,242 | € 573,726 | € 546,209 | € 518,693 | ▼ 5% |
| Retained profit | € 38,641 | € 48,596 | € 68,237 | € 84,637 | ▲ 24% |
| Dividend | € 0 | € 20,000 | € 0 | € 0 | |
| Bank debt | € 586,965 | € 529,961 | € 478,985 | € 423,592 | ▼ 12% |
| Balance sheet total | € 648,540 | € 624,087 | € 572,052 | € 540,740 | ▼ 5% |
Key figures of GLOBIPHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.
What happened to GLOBIPHARM?
What happened at GLOBIPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 16,399 (▼ 17% vs 2024). Source: NBB ↗
- New establishment in Kontich. KBO
- Start of the company according to the CBE. KBO
In short
From € 35,881 profit in 2022 to € 16,399 profit in 2025.
Paid € 20,988 in corporate taxes since 2022.
Best year ever: 2022, with € 35,881 profit.
Paid out € 20,000 in dividends to the owners in total.
A new publication or filing at GLOBIPHARM? We notify you, reason included.
Follow GLOBIPHARMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind GLOBIPHARM are A-Pop Management CommV CommV and Swolfs Consultancy BV BV. The same people are also behind PHARMACEUTICAL ENTERPRISES BELGIUM. A-Pop Management CommV CommV is also behind GLOBIFER INTL.
Directors
According to the 2025 annual accounts
Director · represented by Popowski Anthony
Also active at: PHARMACEUTICAL ENTERPRISES BELGIUM, GLOBIFER INTL
Director · represented by Swolfs Patrick
Also active at: PHARMACEUTICAL ENTERPRISES BELGIUM
Establishments
Establishment units
Physical locations of this company
Satenrozen 6A box 2
2550 Kontich
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 13 companies are registered at this address.
All companies at this address →PHARMACEUTICAL ENTERPRISES BELGIUM same network
€ 53,524 gross margin · 2025
CADIS
€ 986,725 gross margin · 2025
Straalstudio
Schilderstudio
€ 887,895 gross margin · 2025
BJ BTW EENHEID
+8 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0843.002.254
- VAT number
- BE 0843.002.254
- Registered office
- Satenrozen 6A bus 2, 2550 Kontich
- Names & denominations
- GLOBIPHARM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 January 2012
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Handelsbemiddeling in de groothandel in voedings- en genotmiddelen
Groothandel in farmaceutische en medische artikelen